SCHEMBL4922308

SCHEMBL4922308

O=c1[nH]c2cc(Cl)c(Cl)cc2n1-c1ccc(OC(F)(F)F)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.48
POLB P06746 1/20 0.48
MEN1 O00255 2/20 0.44
LMNA P02545 2/20 0.44
KMT2A Q03164 2/20 0.44
OPRM1 P35372 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
TSHR P16473 1/20 0.40
NFKB1 P19838 1/20 0.40
BLM P54132 1/20 0.40
PMP22 Q01453 1/20 0.40
TDP2 O95551 1/20 0.39
HRH3 Q9Y5N1 1/20 0.39
MAPT P10636 1/20 0.39
MAPK1 P28482 1/20 0.39
RECQL P46063 1/20 0.39
TP53 P04637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4930459 0.86 L3MBTL1 (0.49) L3MBTL1POLBMEN1LMNAKMT2A
SCHEMBL4921719 0.84 MAPT (0.43) L3MBTL1POLBMEN1KMT2AOPRM1
SCHEMBL4929661 0.84 HRH3 (0.43) L3MBTL1MEN1LMNAKMT2ASMN1; SMN2
SCHEMBL4934267 0.82 ATM (0.54) L3MBTL1MEN1LMNAKMT2ASMN1; SMN2
SCHEMBL4947302 0.81 HSP90AA1 (0.56) L3MBTL1POLBMEN1LMNAKMT2A
SCHEMBL4928439 0.79 MEN1 (0.50) L3MBTL1MEN1LMNAKMT2ASMN1; SMN2
SCHEMBL17826958 0.78 AURKA (0.48) L3MBTL1POLBMEN1LMNAKMT2A
SCHEMBL4931144 0.77 LMNA (0.48) L3MBTL1MEN1LMNAKMT2ASMN1; SMN2
SCHEMBL4930855 0.77 HRH3 (0.49) L3MBTL1MEN1LMNAKMT2ASMN1; SMN2
SCHEMBL2279270 0.76 ALDH1A1 (0.52) L3MBTL1POLBMEN1LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080021069-A1 Receptor Function Regulating Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-24 US disclosed
US-20080021069-A1 Receptor Function Regulating Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-24 US disclosed
US-20080021069-A1 Receptor Function Regulating Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-24 US disclosed
EP-1810677-A1 RECEPTOR FUNCTION REGULATING AGENT Takeda Pharmaceutical Company Limited (JP) 2007-07-25 EP disclosed
EP-1810677-A1 RECEPTOR FUNCTION REGULATING AGENT Takeda Pharmaceutical Company Limited (JP) 2007-07-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021069-A1 Receptor Function Regulating Agent GPR119, INSR, GPR65 L3MBTL1 4264/4885POLB 4843/4885MEN1 4097/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.